Photo of Iyad Sultan from researchgate.net
Sep 7, 2023, 19:44
Iyad Sultan: A Mixed Bag in Pediatric B-ALL Treatment!
Quoting Iyad Sultan, Chairman and Professor, Department of Pediatrics, King Hussein Cancer Center and a Board Member of OncoDaily, on X/Twitter:
” A Mixed Bag in Pediatric B-ALL Treatment!
AALL1331 Phase III trial finds blinatumomab greatly improves DFS & OS in 2/3 of Low-Risk B-ALL kids with combined BM ± EM relapse, making this a new standard of care.
4-yr DFS: 72.7% vs 53.7% (chemo)
4-yr OS: 97.1% vs 84.8% (chemo)
However, no significant difference was observed for patients with isolated EM relapse. More research is needed.”
Source: Iyad Sultan/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 11, 2025, 09:12
Feb 11, 2025, 08:58
Feb 11, 2025, 08:57
Feb 11, 2025, 08:55
Feb 11, 2025, 08:51
Feb 11, 2025, 08:43